Literature DB >> 14674675

Endoscopic treatment of gastro-oesophageal reflux disease (GORD): a systematic review.

S Contini1, C Scarpignato.   

Abstract

Gastro-oesophageal reflux disease represents an extremely common disorder which has a substantial impact on patients' quality of life and use of health care resources. Gastro-oesophageal reflux disease is a chronic relapsing disease for which a lifelong solution is needed. Until now the two competing therapeutic modalities have been the medical and surgical therapies. Quite recently a third option has become available. A number of endoscopic anti-reflux procedures have been described, with the common goal of creating an anti-reflux barrier, thus obviating long-term proton pump inhibitors and the cost and potential risk of laparoscopic Nissen fundoplication. In this review the different techniques are thoroughly examined and the results are critically evaluated, giving special emphasis to efficacy, safety and durability of these new anti-reflux procedures. Available data show that these anti-reflux techniques produce significant improvement in gastro-oesophageal reflux disease symptomatology and quality of life as well as reduce the use of anti-reflux medication, without causing serious morbidity or mortality. However, the majority of these techniques have failed to adequately control oesophageal acid reflux. Endoscopic anti-reflux therapies therefore sound very attractive-being less invasive than surgery-and show a significant promise, but are still in the early stages of assessment. Large-scale randomized multi-centre trials comparing control groups with sham procedures are essential to confirm their efficacy. Further studies are also necessary to determine what modifications these techniques require in order to produce maximum clinical efficacy and durability. However, considering that current therapies (both medical and surgical) of gastro-oesophageal reflux disease are highly effective, the need for such new endoscopic modalities may be questionable. Moreover, appropriate trials in dedicated centres should be carried out to assure that the enthusiasm commonly associated with new technology is justified and can be generalized to open-access endoscopists.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14674675     DOI: 10.1016/s1590-8658(03)00449-3

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  6 in total

1.  The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease: a cost-effectiveness analysis.

Authors:  Dan Comay; Viviane Adam; Ediardo B da Silveira; Wendy Kennedy; Serge Mayrand; Alan N Barkun
Journal:  Can J Gastroenterol       Date:  2008-06       Impact factor: 3.522

Review 2.  Guide to the use of proton pump inhibitors in adult patients.

Authors:  Vandana Boparai; Jaishree Rajagopalan; George Triadafilopoulos
Journal:  Drugs       Date:  2008       Impact factor: 9.546

3.  Delivery of radiofrequency energy to the gastroesophageal junction (Stretta procedure) for the treatment of gastroesophageal reflux disease.

Authors:  L Cipolletta; G Rotondano; L Dughera; A Repici; M A Bianco; C De Angelis; A M Vingiani; E Battaglia
Journal:  Surg Endosc       Date:  2005-05-03       Impact factor: 4.584

4.  Endoluminal gastroplication in children with significant gastro-oesophageal reflux disease.

Authors:  M Thomson; A Fritscher-Ravens; S Hall; N Afzal; P Ashwood; C P Swain
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

Review 5.  Endoscopic treatment of gastro-oesophageal reflux disease.

Authors:  M A Bianco; G Rotondano; M L Garofano; L Cipolletta
Journal:  Acta Otorhinolaryngol Ital       Date:  2006-10       Impact factor: 2.124

Review 6.  Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression.

Authors:  Carmelo Scarpignato; Luigi Gatta; Angelo Zullo; Corrado Blandizzi
Journal:  BMC Med       Date:  2016-11-09       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.